このページの翻訳は実験的なもので、現在開発中です。お待ちしております

MedPeerInc 将来の成長

Future 基準チェック /16

MedPeerInc利益と収益がそれぞれ年間22%と6.9%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9.7% 22%なると予測されています。

主要情報

4.5%

収益成長率

4.5%

EPS成長率

Healthcare Services 収益成長	15.1%
収益成長率	3.8%
将来の株主資本利益率	8.7%
アナリストカバレッジ	Low
最終更新日	18 Sep 2024

今後の成長に関する最新情報

Recent updates

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

業績と収益の成長予測

TSE:6095 - アナリストの将来予測と過去の財務データ ( )JPY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2027	17,177	930	659	N/A	4
9/30/2026	16,120	842	649	N/A	4
9/30/2025	15,092	745	560	N/A	4
9/30/2024	15,368	1,359	541	N/A	4
6/30/2024	15,303	638	N/A	N/A	N/A
3/31/2024	15,261	436	1,160	1,284	N/A
12/31/2023	15,006	636	N/A	N/A	N/A
9/30/2023	14,540	617	495	600	N/A
6/30/2023	12,691	566	N/A	N/A	N/A
3/31/2023	11,141	594	323	438	N/A
12/31/2022	9,787	712	N/A	N/A	N/A
9/30/2022	8,452	812	691	853	N/A
6/30/2022	8,375	1,004	N/A	N/A	N/A
3/31/2022	8,071	1,121	1,014	1,238	N/A
12/31/2021	7,848	1,226	N/A	N/A	N/A
9/30/2021	7,435	1,293	1,114	1,361	N/A
6/30/2021	7,155	1,183	N/A	N/A	N/A
3/31/2021	6,804	1,154	967	1,170	N/A
12/31/2020	6,308	1,011	N/A	N/A	N/A
9/30/2020	5,311	725	759	930	N/A
6/30/2020	4,457	626	N/A	N/A	N/A
3/31/2020	3,811	510	480	617	N/A
12/31/2019	3,224	418	N/A	N/A	N/A
9/30/2019	3,045	394	262	374	N/A
6/30/2019	2,842	292	N/A	N/A	N/A
3/31/2019	2,672	330	346	437	N/A
12/31/2018	2,414	283	N/A	N/A	N/A
9/30/2018	2,199	206	260	344	N/A
6/30/2018	2,090	-165	N/A	N/A	N/A
3/31/2018	1,921	-262	N/A	189	N/A
12/31/2017	1,745	-327	N/A	N/A	N/A
9/30/2017	1,559	-371	N/A	179	N/A
9/30/2016	973	23	N/A	4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6095の予測収益成長率 (年間22% ) は貯蓄率 ( 0.2% ) を上回っています。

収益対市場: 6095の収益 ( 8.2% ) JP市場 ( 8.6% ) よりも低い成長が予測されています。

高成長収益: 6095の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 6095の収益 ( 3.6% ) JP市場 ( 4.2% ) よりも低い成長が予測されています。

高い収益成長: 6095の収益 ( 6.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6095の自己資本利益率は、3年後には低くなると予測されています ( 9.7 %)。

MedPeerInc 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 31%

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 19%, revenue upgraded

Price target decreased by 9.1% to JP¥1,250

Recent updates

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint